Amber Specialty Pharmacy

Overview

Amber Specialty Pharmacy is a national specialty pharmacy founded in 1998 as one of the first SPs to specialize in transplant care. The company has since expanded into oncology, rare disease, immunology, neurology, fertility, and home infusion services (Amber Specialty Pharmacy). The pharmacy operates 18+ locations across the U.S. and Puerto Rico, with its headquarters in Omaha, Nebraska and additional pharmacy sites in Chicago, Dallas, Philadelphia, Buffalo, Phoenix, and Des Moines (Amber Payer FAQs).

Amber’s clinical model is organized around therapeutic Centers of Excellence (COEs). The Oncology COE includes certified oncology pharmacists and nurses providing individualized care across 15+ cancer types, including breast, lung, colorectal, multiple myeloma, and MDS (Amber Oncology). The Rare Disease Center of Excellence covers neuromuscular disorders, epileptic seizures, bleeding disorders, hemophilia, rare nephrology, graft vs. host disease, and tardive dyskinesia (Amber Rare Disease). In transplant, Amber handles all solid organ transplants (kidney, pancreas, heart, liver, lung) for both pediatric and adult patients, with dedicated Medicare billing and DME expertise (Amber Transplant).

The pharmacy also offers home infusion therapy for oncology and other conditions, with infusion locations in Buffalo, Dallas, Phoenix, Chicago, and Des Moines (Amber Payer FAQs).

Accreditations

• URAC Specialty Pharmacy
• ACHC Specialty Pharmacy
• URAC Rare Disease Pharmacy Center of Excellence

Competitive Positioning

Amber occupies a distinctive niche in the specialty pharmacy landscape: it has the scale and LDN access of a major independent SP (50+ limited distribution networks, 26 million payer lives) while maintaining operational independence from PBMs. Its parent, Hy-Vee, is an employee-owned Midwest grocery chain — not a PBM or health insurer — which gives Amber the ability to position itself as conflict-free to manufacturers (Amber Payer FAQs).

Against PBM-affiliated SPs (CVS Specialty, Accredo, OptumRx Specialty), Amber’s independence positioning is its primary selling point. As stated on its payer materials: “Unlike large conglomerates, we are free to provide custom solutions for our payer partners” (Amber Payer FAQs). Against other independents like PANTHERx Rare, Amber differentiates through therapeutic breadth — covering transplant, oncology, rare disease, immunology, neurology, and fertility — rather than specializing in a single niche. Its transplant heritage remains a strong differentiator; it was the pharmacy of choice for many of the nation’s most prestigious transplant programs from inception (Amber Transplant).

Amber earned the NASP Specialty Pharmacy of the Year award in both 2020 and 2024, a significant industry recognition (Amber 2024 Award; Hy-Vee 2020 Award).

Recent Developments (2024–2026)

• 2024: Named NASP Specialty Pharmacy of the Year for the second time (Amber 2024 Award).
• 2025: Partnered with Massive Bio for a nationwide oncology clinical trial recruitment initiative, combining Amber’s 26 million payer lives and 50+ LDNs with Massive Bio’s AI-enabled trial matching platform covering 60,000 cancer patients across 12 countries (Massive Bio).
• 2025 (Dec): Launched R.A.I. (Record Access Integration) EHR technology; reduced non-therapy calls 60% with automated communications.
• 2024 (Mar): Began dispensing Rezdiffra (Madrigal) for NASH.
• 2022: Earned URAC Rare Disease Pharmacy Center of Excellence designation (Business Wire).
• 2021: Selected by Takeda to dispense LIVTENCITY (maribavir) for post-transplant CMV infection, the first treatment indicated for refractory post-transplant CMV (Amber LIVTENCITY).
• Added to Eisai’s LDN for oncology products (Amber Oncology).
• Listed on the REVLIMID (lenalidomide) REMS Pharmacy Network for Bristol Myers Squibb (BMS Access Support).

Client & Partner Ecosystem

Amber partners with major pharmaceutical manufacturers for LDN-distributed specialty drugs across transplant, oncology, and rare disease. Named partners include Takeda (LIVTENCITY for transplant CMV), Eisai (oncology), Bristol Myers Squibb (lenalidomide/REVLIMID REMS network), Madrigal (Rezdiffra), Amgen (Tezspire, BRINSUPRI), and Greenwich Biosciences (launch partner, OLE/EAP transition). The Massive Bio partnership positions Amber as a pipeline for oncology clinical trial recruitment as well (Massive Bio).

Amber’s 26 million payer lives figure indicates significant PBM/payer network coverage, and 50+ LDN contracts suggest broad manufacturer relationships across multiple therapeutic categories (Massive Bio).

Technology partners include WeInfuse (Specialty Pharmacy Connect).

Technology Platform

Amber’s most notable technology capability is its proprietary AI/ML-based predictive adherence model. The system analyzes multiple patient data points — including zip code, diagnosis, prescribing physician, and historical patterns — to flag patients at high risk for non-adherence before they lapse. Flagged patients receive proactive outreach from care teams plus additional automated phone or text touchpoints (Amber AI/ML).

Additional technology includes:

• R.A.I. (Record Access Integration) — EHR integration technology launched December 2025
• All-in-one patient portal (my.amberpharmacy.com) for refills, payments, delivery tracking, and chat with pharmacy staff
• Mobile app with refill ordering, payment, and delivery status
• EHR integration for faster dispense times
• AdhereTech partnership — smart pill bottles that alert pharmacy staff when patients miss doses
• Text-based refill reminders and shipping alerts (Amber Payer FAQs)

Therapeutic Focus

Transplant (all solid organ — kidney, pancreas, heart, liver, lung), Oncology (15+ cancer types), Rare Disease (neuromuscular, epilepsy, bleeding disorders, hemophilia, rare nephrology, GvHD, tardive dyskinesia), Immunology, Neurology, Fertility, Home Infusion, plus MS, RA, HIV/AIDS, hepatitis, bleeding disorders

Financial Context

Amber Specialty Pharmacy is a wholly owned subsidiary of Hy-Vee, Inc., an employee-owned corporation headquartered in West Des Moines, Iowa with 250+ retail locations. Hy-Vee acquired Amber in 2014 after a four-year partnership. At acquisition time (2012 figures), Amber had 130 employees and $155M in revenue (Drug Topics). Current third-party estimates suggest ~$93M revenue and ~461 employees (Growjo; LeadIQ). However, these estimates may undercount given the 50+ LDNs and 26 million payer lives figure, which typically implies significantly higher revenue. In 2019, Amber’s teams saved patients over $42 million through grants and financial assistance alone (Amber Payer FAQs).

Hy-Vee ownership provides financial stability and access to retail pharmacy infrastructure, though it limits growth capital relative to PE-backed competitors.

Estimated revenue: $50M–$100M (estimated; $155M reported in 2012 pre-acquisition; third-party estimates suggest ~$93M current)

Key Leadership

• Kristin Williams — President, Amber Specialty Pharmacy / EVP & Chief Health Officer, Hy-Vee

Analyst Observations

Strengths: Amber’s combination of 50+ LDNs, URAC Rare Disease COE designation, dual URAC/ACHC accreditation, and PBM-independence makes it one of the stronger independent SPs in the U.S. Its transplant heritage provides a defensible niche that few competitors can replicate. The AI adherence model, while not unique conceptually, is among the more developed implementations in the independent SP space.

Acquisition potential: Moderate-to-high. Amber sits inside Hy-Vee, a grocery chain without strategic synergy in specialty pharmacy. A divestiture to a PE firm, hub services company, or health system seeking SP capabilities is plausible. Companies like Eversana, ConnectiveRx, or a health system building 340B specialty pharmacy capabilities could be interested.

Risks: Revenue growth may be constrained under Hy-Vee ownership, which has limited healthcare strategic focus. Hy-Vee’s employee-owned structure makes PE-style value creation plays difficult. The third-party revenue estimates (~$93M) suggest Amber may have plateaued relative to faster-growing peers like Senderra ($2B+) and PANTHERx ($1B+).

Category Links

• Primary category: Specialty Pharmacies
• Secondary: Infusion & Clinical Services
• Secondary: Prior Authorization & Reimbursement
• Secondary: Copay & Financial Assistance

Sources

• Amber Pharmacy About, Amber Biopharma, Amber Payer FAQs, Amber Oncology, Amber Rare Disease, Amber Transplant, Amber AI/ML, Amber 2024 Award, Massive Bio Partnership, Business Wire URAC COE, Drug Topics Acquisition, LinkedIn, Growjo, BMS Access Support